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MORPHINE-6-SULFATE ANALOGUES AND 
THEIR USE FOR THE TREATMENT OF 
PAIN 
RELATED APPLICATIONS 
This application is a continuation of application Ser. No. 
08/881,288 ?led Jun. 24, 1997 noW abandoned: Which is a 
continuation-in-part of application Ser. No. 08/803,312, 
?led Feb. 20, 1997 noW abandoned. 
Technical Field 
The present invention relates to 3-O-Acetylmorphine-6 
sulfate compounds and their ester derivatives Which are 
potent, centrally-acting morphine derivatives. The com 
pounds are useful for the treatment of pain. 
BACKGROUND ART 
The opiate analgesic morphine, When administered to 
humans, is converted by the liver into three major 
metabolites, viZ. morphine-3-O-glucuronide (M3G), 
morphine-6-O-glucuronide (M6G) and morphine-3-O 
sulfate (M3S) [9,19]. M6G is found in the systemic circu 
lation in concentrations exceeding those of morphine itself, 
after both parenteral [12,19] and oral administration [12,18]. 
M6G is a very potent p-receptor agonist [3] With a high 
af?nity for both mu1 and mu2 receptors [1,14] and appears 
to cross the blood-brain barrier in spite of its high polarity 
compared to morphine [20]. 
Some morphine compounds are knoWn in the art. For 
example, US. Pat. No. 5,219,861 to Kanematsu et al. relates 
to a novel morphine-6-thiol derivatives. Kanematsu dis 
closes acetylthio-derivatives on the siX position of morphine 
and esters on position three. 
US. Pat. Nos. 4,496,570 to Bodor and 5,352,680 to 
Portoghese et al. relates to opiates With heterocyclic sub 
stituents bound to position siX of the opiate ring. Both 
patents disclose thiol ring substituents on morphine. 
US. Pat. No. 4,362,870 to Portoghese relates to a non 
addictive analgesic opiate. Portoghese further discloses 
morphine-like opiates Which have substituted isothiocyanate 
groups on position siX and ester groups on position three of 
the opiate. 
US. Pat. No. 5,258,512 to Heiman et al. relates to a 
method for a ?uorescence polariZation immunoassay proce 
dure for determining the amount opiate alkaloids in ?uids. 
The invention discloses, in FIG. 13-9, the use of a morphine 
sulfonamide on position siX. 
Houdi et al., PharmacoL, Biochem. & Behavior (March, 
1996) disclosing morphine-6-sulfate esters and their anal 
gesic character. This is the Work of the present inventors. 
BroWn et al., J. Pharm. Sci. 74:821—24 (August, 1985) 
relates to the analgesic potencies of several morphine ana 
logues With covalent modi?cations at carbons 3 and 6. 
Speci?cally, morphine-6-sulfate is disclosed. 
Choonara et al., J. Clin. Pharmacol. 30:897—900 
(December, 1990) describes the metabolism of morphine 
and the detection of morphine-3 and morphine-6-sulfate. 
Oguri et al., Eur J. Pharmacol. 102:229—35 (July, 1984) 
relates to the dependency of nalorphine-6-sulfate conju 
gates. 
Hirano et al., Chem. Pharm. Bull. 39:2000—4 (August, 
1991) relates to the synthesis and pharmacological activity 
of nalorphine-6-sulfate conjugates. 
There is a need in the art for effective treatments for 
relieving pain in animals and humans. The present invention 
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2 
overcomes de?ciencies in the prior art in providing neW and 
effective treatments for pain, and other conditions Whose 
symptoms are knoWn to be alleviated With morphine com 
pounds. 
DISCLOSURE OF THE INVENTION 
The present invention relates to morphine analogues, 
substituted With both a sulfate group at position siX of the 
ring and an ester group at position three. The compounds are 
used as analgesics and for the treatment of pain. 
More particularly the compounds selected from the group 
consisting of the folloWing formulas I and II: 
Formula I 
X 05036 
Wherein X is selected from the group consisting of 
—OR2, 
OC—R3, 
and 
Wherein R1 may be a straight or branched chain alkyl or 
alkenyl group having 1—5 carbon atoms; 
Wherein R2 is an alkyl having 1—3 carbon atoms, and 
Wherein R3 is H or n-alkyl or branched alkyl With 1—10 
carbon atoms (preferably 4—8 carbon atoms), 
cycloalkyl, aralkyl, n-alkenyl or branched alkenyl 
With 1—10 carbon atoms, and n-alkynyl or branched 
alkynyl With 1—10 carbon atoms. R3 is preferably 
OCH3, OCOCH3, OCOCH2CH3, OCOCH(CH3)2, 
OCOCH(CH3)3 and OCO-phenyl. 
Formula II 
X 05036 
Wherein X is selected from the group consisting of 
—OR2, 
US 6,403,602 B1 
and 
wherein R1 may be a straight or branched chain alkyl or 
alkenyl group having 1—5 carbon atoms; 
Wherein R2 is an alkyl having 1—3 carbon atoms, and 
Wherein R3 is H or n-alkyl or branched alkyl With 1—10 
carbon atoms, cycloalkyl, aralkyl, n-alkenyl or 
branched alkenyl With 1—10 carbon atoms 
(preferably 4—8 carbon atoms), and n-alkynyl or 
branched alkynyl With 1—10 carbon atoms. R3 is 
preferably selected from the group consisting of 
OCH3, OCOCH3, OCOCH2CH3. 
The above and other objects of the invention Will become 
readily apparent to those of skill in the relevant art from the 
folloWing detailed description and ?gures, Wherein only the 
preferred embodiments of the invention are shoWn and 
described, simply by Way of illustration of the best mode of 
carrying out the invention. As is readily recogniZed the 
invention is capable of modi?cations Within the skill of the 
relevant art Without departing from the spirit and scope of 
the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shoWs structures of morphine and morphine-6-O 
sulfate derivatives. 
FIG. 2 shoWs antinociceptive response to subcutaneous 
treatment With morphine. Antinociception is shoWn as the 
percent of maximum possible response in the tail-?ick test. 
Free base morphine Was used for subcutaneous administra 
tion (5 mg/kg, 0.0175 mmole) Equimolar doses of morphine 
derivatives Were as folloWs: M6S (6.4 mg/kg); M3A6S (7.1 
mg/kg); M3B6S (8.2 mg/kg); and MM3A6S (7.4 mg/kg) 
Were administered subcutaneously. Predrug response laten 
cies for saline, morphine, M6S, M3A6S, M3B6S, and 
MM3A6S Were 2.15, 1.96, 2.37, 1.79, 1.95 and 2.11 seconds 
respectively. 
FIG. 3 shoWs antinociceptive response to treatment With 
saline vehicle, morphine and morphine derivatives. For 
intracerebroventricular drug administration, 2 doses of mor 
phine Were used; loW dose morphine (0.236 pig/rat, 0.83 
pmole pmole/rat as free base) and high dose of morphine 
(23.6 pig/rat, 83 pmole/rat). Doses of morphine derivatives 
administered intracerebroventricularly Were equimolar to 
the loW dose of morphine and Were as folloWs: M6S (0.22 
pig/kg) ; M3A6S (0.25 pig/kg) ; M3B6S (0.29 pig/kg); and 
MM3A6S (0.26 pig/kg). Antinociception is shoWn as the 
percent of maximum possible response in the tail-?ick test. 
Predrug response latencies for saline, morphine loW dose, 
morphine high dose, M6S, M3A6S, M3B6S, and MM3A6S 
Were 2.05, 2.06, 1.69, 1.92, 2.62, 2.06 and 1.82 seconds 
respectively. 
FIG. 4 shoWs precipitated morphine WithdraWal With time 
after the administration of morphine in the Rhesus monkey. 
Precipitated WithdraWal test initiated by injection of mor 
phine control 2.5 hrs after an injection and animals observed 
for signs of WithdraWal. Time on the abscissa represents time 
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after administration of morphine control. On the ordinate is 
the cumulative WithdraWal signs Which are composed of unit 
scores given that record the manifestation of characteristic 
WithdraWal symptoms. Injection vehicle: saline. 
FIG. 5 shoWs precipitated morphine WithdraWal With time 
after the administration of M3A6S in the Rhesus monkey. 
Precipitated WithdraWal test initiated by the injection of 
M3A6S 2.5 hrs after an injection of morphine and animal 
observed for signs of WithdraWal. All experimental condi 
tions are similar to that in FIG. 4 except that the injection 
vehicle is 25% TWeen in Water With gentle Warming. 
FIG. 6 shoWs precipitated morphine WithdraWal With time 
after the administration of DM3A6S in the Rhesus monkey. 
Precipitated WithdraWal test initiated by the injection of 
DM3A6S 2.5 hrs after an injection of morphine and animal 
observed for signs of WithdraWal. All experimental condi 
tions are similar to that in FIG. 4. 
FIG. 7 shoWs the analgesic pro?le of M65. Effect of 
morphine 6-O-sulfate (M65) in comparison to morphine on 
nociception after subcutaneous (s.c.) administration in the 
rat tail ?ick (RTF) assay. Dose of morphine and M65 
administered: 0.0175 mmol/kg Wt. of animal/ml. Injection 
vehicle: sesame seed oil, n=5. Time on the abscissa repre 
sents time relative to morphine administration. Antinocice 
ption is shoWn as the percent of maximum possible analge 
sia (%MPA). Pre-drug response latencies (basal analgesia) 
for morphine and M65 Were 2.01 and 2.23, respectively. 
FIG. 8 shoWs the analgesic pro?le of M3A6S. Effect of 
3-O-acetylmorphine-6-O-sulfate (M3A6S), in comparison 
to morphine, on nociception after so administration in the 
RTF assay. All experimental details remain the same (as 
described in FIG. 7) except that for M3A6S, n=4 and the 
basal analgesia value is 1.77. 
FIG. 9 shoWs the analgesic pro?le of M3Pr6S. Effect of 
3-O-propionylmorphine-6-O-sulfate (M3Pr6S), in compari 
son to morphine, on nociception after so administration in 
the RTF assay. All experimental details remain the same (as 
described in FIG. 7) except that for M3Pr6S, n=3 and the 
basal analgesia value is 1.97. 
FIG. 10 shoWs the analgesic pro?le of M3Ibu6S Effect of 
3-O-isobutyrylmorphine-6-O-sulfate (M3Ibu6S), in com 
parison to morphine, on nociception after so administration 
in the RTF assay. All experimental details remain the same 
(as described in FIG. 7) except that for M3Ibu6S, n=4 and 
the basal analgesia value is 1.86. 
FIG. 11 shoWs analgesic pro?le of M3P6S Effect of 
3-O-pivaloylmorphine-6-O-sulfate (M3P6S), in comparison 
to morphine, on nociception after so administration in the 
RTF assay. All experimental details remain the same (as 
described in FIG. 7) except that for M3P6S, n=6 and the 
basal analgesia value is 1.95. 
FIG. 12 shoWs analgesic pro?le of M3B6S Effect of 
3-O-benZoylmorphine-6-O-sulfate (M3B6S), in comparison 
to morphine, on nociception after so administration in the 
RTF assay. All experimental details remain the same (as 
described in FIG. 7 except that for M3B6S, n=3 and the 
basal analgesia value is 1.91. 
FIG. 13 shoWs analgesic pro?le of DM3A6S Effect of 
3-O-acetyl-7,8-dihydromorphine-6-O-sulfate (DM3A6S), in 
comparison to morphine, on nociception after so adminis 
tration in the RTF assay. All experimental details remain the 
same (as described in FIG. 7) except that for DM3A6S, n=3 
and the basal analgesia value is 1.90. 
US 6,403,602 B1 
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FIG. 14 shows analgesic pro?le of DM3B6S Effect of 
3-O-benZoyl-7,8-dihydromorphine-6-O-sulfate (DM3B6S), 
in comparison to morphine, on nociception after so admin 
istration in the RTF assay. All experimental details remain 
the same (as described in FIG. 7) except that for DM3B6S, 
n=4 and the basal analgesia value is 1.78. 
FIG. 15 shoWs analgesic pro?le of MM3A6S, Effect of 
3-O-acetyl-N-methylmorphinium-6-O-sulfate (MM3A6S), 
in comparison to morphine, on nociception after so admin 
istration in the RTF assay. All experimental details remain 
the same (as described in FIG. 7) except that for MM3A6S, 
n=5 and the basal analgesia value is 2.03. 
FIG. 16 shoWs analgesic pro?le of MM3B6S. Effect of 
3-O-benZoyl-N-methylmorphinium-6-O-sulfate 
(MM3B6S), in comparison to morphine, on nociception 
after so administration in the RTF assay. All experimental 
details remain the same (as described in FIG. 7) except that 
for MM3B6S, n=4 and the basal analgesia value is 2.23. 
DESCRIPTION OF THE INVENTION 
The present invention relates to 3-O-Acetylmorphine-6 
sulfate compounds and their ester derivatives Which are 
potent, centrally-acting morphine derivatives. The com 
pounds are useful for the treatment of pain. 
The folloWing is a list of abbreviations Which appear 
throughout the application. 
CNS: Central Nervous System 
GI: Gastrointestinal 
PETT: Position emission transaxial tomography 
ATP: 5'—adenosine triphosphate 
cAMP: Cyclic 3',5'—adenosine monophosphate 
MHP: Mouse hot plate assay 
UDPGA: Uridine diphosphate glucuronic acid 
M6S: Morphine-6-O-sulfate 
M3A6S: 3-0—Acetylmorphine-6-O-sulfate 
M3Pr6S: 3-0-Propionylmorphine-6-O-sulfate 
APS: Adenosine 5 '-sulfatophosphate 
PAPS: 3'—phosphoadenosine-5'—phosphosulfate 
M3P6S: 3-0-Pivaloylmorphine-6-0-sulfate 
M3B6S: 3-0-Benzoylmorphine-6-0-sulfate 
DM3B6S: 3-0-Benzoyl-7,8-dihydromorphine-6-O-sulfate 
M6G: Morphine-6-O-glucuronide 
M3G: Morphine-3-O-glucuronide 
i.c.v.: Intracerebroventricular 
i.p.: Intraperitoneal 
CSF: Cerebro-spinal ?uid 
DADL: D-alanine D-leucine 
DM: 7,8-Dihydromorphine 
DM6S: 7,8-Dihydromorpihine-6-O-sulfate 
MM3A6S: 3-0-Acetyl N-methylmorphinium-6-O-sulfate 
MM3B6S: 3-0-Benzoyl N-methylmorphinium-6—O—sulfate 
s.c.: Sub-cutaneous 
TLC: Thin Layer chromatography 
HETCOR: Hetero-atom chemical shift correlation 
COSY: Homonuclear correlation 
DEPT: Distortionless enhancement by polarization 
transfer 
FABMS: Fast atom bombardment mass spectroscopy 
RTF: Rat Tail Flick 
% MPE: Percentage of maximum possible effect 
% MPA: Percentage of maximum possible analgesia 
SDA: Single dose suppression 
PPt-W: Precipitated Withdrawal 
CP/MAS: Cross polarization, magic angle spinning 
SAR: Structure-activity relationship 
TMS: Tetramethyl silane 
ADTN: 2-Amino-6,7-dihydroxytetrahydronaphthalene 
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In vieW of the potent analgesia exhibited by the apparent 
structurallydissimilarmorphine-6-O-glucuronide (M6G) and 
morphine-6-O-sulfate (M6S) conjugates of morphine, the 
effect of structural modi?cation of M6S on analgesic activity 
has been examined using the tail-?ick test. Changes in the 
M6S structure Were made that Would affect the lipophilicity 
and polarity of the molecule. Subcutaneous (sc) and intrac 
erebroventricular (icv) administration of equimolar doses of 
morphine, M6S, 3-O-acetylmorphine-6-O-sulfate (M3A6S), 
3-O-benZoylmorphine-6-O-sulfate (M3B6S) and 3-O 
acetyl-N-methylmorphinium-6-O-sulfate (MM3A6S) Were 
employed. 
M6S and M3A6S unexpectedly exhibited a longer dura 
tion of action and greater activity compared to morphine 
after Sc and icv administration. HoWever, M3B6S and 
MM3A6S in a doses equimolar to that of morphine Were 
found to be inactive after both Sc and icv administration. In 
addition, M3A6S shoWed the highest potency in inhibiting 
electrically stimulated guinea pig ileum folloWed by M6S 
and M3B6S. Moreover, both M6S and M3A6S displayed a 
greater af?nity than that of morphine to mu and kappa3 
receptor sites in guinea pig brain homogenate. 
In contrast, the non-analgesic compounds M3B6S and 
MM3A6S shoWed Weak receptor binding ability compared 
to morphine. These results indicate that lipophilicity alone is 
not a determinant of analgesic activity in these novel mor 
phine derivatives. These modi?ed effects of morphine by the 
conjugations at the 3- and 6-position, appear to be due to 
their altered interactions With opioid receptors 
After examining the clinical activity of M6G in a group of 
cancer patients, it has been concluded that the analgesic 
effect of administered morphine is due mainly to metaboli 
cally formed M6G rather than to morphine itself [11]. 
Interestingly, the conjugate, morphine-6-O-sulfate (M6S) 
Was shoWn to exhibit more potent and longer acting anal 
gesia than morphine itself in mice On the other hand, 
M6S shoWed comparatively reduced competing potencies 
toWard mu-receptors but enhanced delta-receptor affinity 
compared to parent compound morphine [10]. 
In vieW of the potent analgesia exhibited by the apparent 
structurally dissimilar 6-O-glucuronide and 6-O-sulfate con 
jugates of morphine, the effect of structural modi?cation on 
antinociceptivity in the M6S molecule Was examined. Of 
particular interest Was the effect of increasing lipophilicity 
on activity by esteri?cation of the 3-hydroxy group and the 
effect of increasing polarity by conversion of M6S to its 
N-methyl morphinium betaine (see FIG. 1). 
As part of these structure-activity studies, the inventors 
report on the potent, centrally-acting antinociceptive activity 
of the morphine derivative, 3-O-acetylmorphine-6-O 
sulfate, in the rat. 
















